Anti-Human Fibroblast Growth Factor 23 (Burosumab)

Research-grade Burosumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays by serving as the analytical standard to generate a reference concentration curve, enabling quantification of Burosumab levels in test serum samples. This approach ensures assay consistency and comparability for both biosimilar and reference products.

Key details on their use include:

• Analytical Standard/Calibration Curve: The biosimilar, characterized for purity and concentration, is serially diluted to prepare calibration standards over a range of concentrations (e.g., 50–12,800 ng/mL) in a matrix matched to study samples, such as human serum. These standards are included in each assay run to generate a standard curve, against which unknown serum sample concentrations are interpolated.

• Reference Controls: QC samples can be prepared from both the biosimilar and the reference (originator) Burosumab to test assay performance, establishing that the ELISA quantifies both products equivalently when employing the biosimilar as the calibration standard.

• Assay Bridging Rationale: Regulatory guidance and bioanalytical best practice recommend the use of a single, well-characterized standard (often the biosimilar) to minimize variability and facilitate direct comparison between biosimilar and reference product PK profiles in the assay. Equivalence in quantitation is established statistically during assay validation and qualification.

• In the ELISA process:

  • Capture antibodies specific to Burosumab are pre-coated onto ELISA plates.
  • Serum samples, calibrator (biosimilar) standards, and QC reference controls are added.
  • After incubation and washing, a detection antibody (often enzyme-linked) is added, followed by substrate for signal development.
  • The developed signal corresponds to Burosumab concentration, interpolated from the standard curve based on the biosimilar standard.

In summary, research-grade Burosumab biosimilars function as the quantitation anchor for PK ELISAs—serving as the standard against which both biosimilar and reference product concentrations are measured in serum, and as reference controls to ensure assay comparability and accuracy. This ensures robust bioanalytical comparability essential for PK bridging studies in biosimilar development.

The primary preclinical models used to administer research-grade anti-FGF23 antibodies in vivo for studying tumor growth inhibition and characterizing tumor-infiltrating lymphocytes (TILs) are mouse syngeneic tumor models. There is no clear evidence in the current literature that humanized models have been routinely used for anti-FGF23 antibody studies focused on TIL characterization.

Essential Context and Supporting Details:

• Syngeneic models involve implantation of mouse-derived tumor cell lines into immunocompetent mice of the same genetic background, allowing the study of tumor-immune interactions, TIL profiles, and therapeutic antibody effects in the context of a fully functional murine immune system.

• These models are specifically favored for immunotherapy research, including studies of immune checkpoint inhibitors and profiling of TILs by flow cytometry, due to the presence of mouse-origin immune cells that accurately reflect the in vivo immune response to treatments.

• Anti-FGF23 antibody intervention: Several studies and reviews discuss the use of anti-FGF23 antibodies or inhibitors to modulate tumor growth, particularly in cancers with elevated FGF23 signaling (e.g., multiple myeloma, prostate cancer, or bone tumors), and suggest that in vivo efficacy and immune profile changes—including TIL characterization—are best examined using mouse syngeneic models.

• While humanized mouse models (e.g., NSG mice engrafted with human immune cells) are used for certain immuno-oncology studies, they are not commonly referenced in the literature for anti-FGF23 antibody evaluation with a focus on TILs, likely due to technical complexity and limitations in recapitulating human FGF23-immune interactions.

Additional Relevant Information:

• Multiple syngeneic tumor models (MC38, CT26, RENCA, B16F10, TC-1, etc.) are widely used to enable comparative profiling of immune infiltrates following antibody treatment, providing critical data for preclinical immunotherapy development.

• TIL characterization in these studies typically uses multicolor flow cytometry and gene expression profiling to analyze how interventions (such as anti-FGF23 antibodies) impact the immune composition within the tumor microenvironment.

• For cancers with significant bone involvement, the biological impact of FGF23 (and its therapeutic targeting) appears especially relevant; mouse models of these tumor types are standard platforms for discovery and validation studies.

In summary, syngeneic mouse tumor models are the predominant platform where research-grade anti-FGF23 antibodies are administered in vivo to study both tumor growth inhibition and the characterization of TILs. Humanized models are mainly reserved for translational studies requiring human-specific immune responses and are less commonly utilized for anti-FGF23 and TIL research.

Researchers commonly use Burosumab biosimilars—which target and neutralize FGF23 signaling—in complex immune-oncology models to investigate how modifying the tumor microenvironment or host metabolism might interact with or potentiate the effects of immune checkpoint inhibitors such as anti-CTLA-4 and anti-LAG-3 biosimilars. This approach typically involves combining Burosumab with checkpoint inhibitors to evaluate synergistic effects on tumor immunity or therapeutic outcomes in preclinical models.

Context and Supporting Details:

• Burosumab biosimilar functions by blocking FGF23, a hormone linked to phosphate metabolism and bone health. Though its primary research applications are in metabolic and bone diseases such as X-linked hypophosphatemia (XLH), researchers are investigating its impact on the immune system and tumor environments, as FGF23 pathways may modulate immune cell function.

• Checkpoint inhibitors (e.g., anti-CTLA-4, anti-LAG-3 biosimilars) block negative regulators of T-cell activation, unleashing immune responses against tumor cells. These inhibitors act through distinct immune pathways—CTLA-4 mainly affects early T-cell activation, while LAG-3 inhibits T-cell proliferation and function in the tumor microenvironment.

Synergy Studies:

• Combining Burosumab with checkpoint inhibitors in experimental models allows researchers to study synergistic effects such as:

  • Enhanced T-cell activation or infiltration into tumors.
  • Changes to the immunosuppressive tumor microenvironment mediated by FGF23 pathway blockade.
  • Effects on bone and mineral metabolism that might indirectly influence immune cell energetics or trafficking.

• These combinations are assessed in functional assays and advanced animal models. Endpoints often include tumor growth inhibition, immune cell profiling, and analyses of cytokine production or bone phenotype changes.

• Researchers select biosimilars rather than clinical-grade antibodies for cost, consistency, and reproducibility in basic and translational studies.

Additional Notes:

• There is no direct clinical evidence yet for Burosumab/checkpoint inhibitor combinations; current research is largely preclinical or exploratory.
• The complexity of these studies allows for testing multi-dimensional immune and metabolic responses that are relevant for developing new combinatorial cancer therapies.

In summary, researchers use Burosumab biosimilars with other checkpoint inhibitors in immuno-oncology models to dissect interactions between tumor immunity, metabolism, and immune regulation, focusing on functional and synergistic effects in controlled experimental systems.

API Error 503: <html><body><h1>503 Service Unavailable</h1>No server is available to handle this request.<script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'986e2e6c9f0f4de2',t:'MTc1OTE3NzIzMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head').appendChild(a);";b.getElementsByTagName('head').appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body></html>